Alpelisib (BYL719) ( DrugBank: Alpelisib )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
138神経細胞移動異常症1

138. 神経細胞移動異常症


臨床試験数 : 1 薬物数 : 2 - (DrugBank : 1) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 106
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05577754
(ClinicalTrials.gov)
November 28, 202210/10/2022Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)A Phase II Double-blind Multi-center, Placebo-controlled Trial, to Assess the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)Drug: Alpelisib (BYL719);Drug: Matching placebo;Procedure: Optional lumbar punctureCentre Hospitalier Universitaire DijonNULLRecruiting2 Years40 YearsAll16Phase 2France